New hope for stomach cancer patients with abdominal spread: experimental drug combo enters trial
NCT ID NCT07384234
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding an experimental immunotherapy drug called SHR-1701 to standard chemotherapy can help people with stomach cancer that has spread to the lining of the abdomen. The study will enroll 60 adults and compare two different chemotherapy combinations, with or without SHR-1701. The main goal is to see if the treatment improves survival over two years and whether it can make the cancer removable by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1701 (an experimental immunotherapy drug) combined with chemotherapy drugs (paclitaxel, S-1, capecitabine, oxaliplatin)
What this could lead to
If successful, this could offer a new treatment option for people with stomach cancer that has spread to the abdomen, potentially improving survival and making surgery possible.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results are preliminary. The combination may cause significant side effects, and the experimental drug SHR-1701 may not improve outcomes over standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
Shanghai, Shanghai Municipality, China
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact